FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309108432> ?p ?o ?g. }

• W4309108432 endingPage "A015" @default.
• W4309108432 startingPage "A015" @default.
• W4309108432 abstract "Abstract Amplia Therapeutics Limited is developing AMP945, a highly selective inhibitor of Focal adhesion kinase (FAK) for the treatment of pancreatic cancer in combination with standard of care gemcitabine and nab-paclitaxel.1 FAK has been associated with the activity of myofibroblasts and collagen deposition and remodeling in PDAC. In preclinical studies, AMP945 displays potent anti-fibrotic activity in vitro and in vivo. In mouse models of PDAC, pulsed dosing of AMP945 added to gemcitabine and nab-paclitaxel inhibited collagen deposition and cross-linking and potentiated the effect of chemotherapy leading to increased survival.2A Phase 1 trial of AMP945 has been completed in which AMP945 showed excellent safety, tolerability, and pharmacokinetic properties as well as pharmacodynamic evidence of target engagement. Amplia’s recently initiated Phase 1b/2a clinical trial AMP945-PC-2013 (ACCENT) will assess a pulse dosing regimen of AMP945 in combination with gemcitabine and nab-paclitaxel as first-line therapy in patients with advanced pancreatic cancer. In ACCENT, patients will undergo a one-week oral loading dose of AMP945 and will be pulse dosed for four days prior to IV administration of gemcitabine and nab-paclitaxel, given according to a standard treatment schedule. Once daily oral dosing has anticipated benefits in terms of limitation of risk of acquired resistance, minimal potential for drug-drug interactions, adherence to therapy, and allows patients to self-administer AMP945 with the aim of potentiating response to standard of care chemotherapy. This abstract presentation will report on AMP945’s development status and the clinical rationale and status of the ACCENT trial. 1. Von Hoff et al., N Engl J Med 2013; 369:1691-1703 2. Murphy KJ et al. Sci Adv. 2021 Oct;7(40):eabh0363. 3. https://clinicaltrials.gov/ct2/show/NCT05355298 Citation Format: John Lambert, Mark Devine, Anthony Bishop. Rationale for the use of pulsed rather than continual dosing of the novel Focal Adhesion Kinase inhibitor AMP945 in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A015." @default.
• W4309108432 created "2022-11-22" @default.
• W4309108432 creator A5003389239 @default.
• W4309108432 creator A5070640888 @default.
• W4309108432 creator A5076748839 @default.
• W4309108432 date "2022-11-15" @default.
• W4309108432 modified "2023-09-30" @default.
• W4309108432 title "Abstract A015: Rationale for the use of pulsed rather than continual dosing of the novel Focal Adhesion Kinase inhibitor AMP945 in pancreatic cancer" @default.
• W4309108432 doi "https://doi.org/10.1158/1538-7445.panca22-a015" @default.
• W4309108432 hasPublicationYear "2022" @default.
• W4309108432 type Work @default.
• W4309108432 citedByCount "0" @default.
• W4309108432 crossrefType "journal-article" @default.
• W4309108432 hasAuthorship W4309108432A5003389239 @default.
• W4309108432 hasAuthorship W4309108432A5070640888 @default.
• W4309108432 hasAuthorship W4309108432A5076748839 @default.
• W4309108432 hasConcept C111113717 @default.
• W4309108432 hasConcept C112705442 @default.
• W4309108432 hasConcept C121608353 @default.
• W4309108432 hasConcept C126322002 @default.
• W4309108432 hasConcept C143998085 @default.
• W4309108432 hasConcept C197934379 @default.
• W4309108432 hasConcept C2776694085 @default.
• W4309108432 hasConcept C2777288759 @default.
• W4309108432 hasConcept C2777292972 @default.
• W4309108432 hasConcept C2778375690 @default.
• W4309108432 hasConcept C2780210213 @default.
• W4309108432 hasConcept C2780258809 @default.
• W4309108432 hasConcept C71924100 @default.
• W4309108432 hasConcept C98274493 @default.
• W4309108432 hasConceptScore W4309108432C111113717 @default.
• W4309108432 hasConceptScore W4309108432C112705442 @default.
• W4309108432 hasConceptScore W4309108432C121608353 @default.
• W4309108432 hasConceptScore W4309108432C126322002 @default.
• W4309108432 hasConceptScore W4309108432C143998085 @default.
• W4309108432 hasConceptScore W4309108432C197934379 @default.
• W4309108432 hasConceptScore W4309108432C2776694085 @default.
• W4309108432 hasConceptScore W4309108432C2777288759 @default.
• W4309108432 hasConceptScore W4309108432C2777292972 @default.
• W4309108432 hasConceptScore W4309108432C2778375690 @default.
• W4309108432 hasConceptScore W4309108432C2780210213 @default.
• W4309108432 hasConceptScore W4309108432C2780258809 @default.
• W4309108432 hasConceptScore W4309108432C71924100 @default.
• W4309108432 hasConceptScore W4309108432C98274493 @default.
• W4309108432 hasIssue "22_Supplement" @default.
• W4309108432 hasLocation W43091084321 @default.
• W4309108432 hasOpenAccess W4309108432 @default.
• W4309108432 hasPrimaryLocation W43091084321 @default.
• W4309108432 hasRelatedWork W1552629127 @default.
• W4309108432 hasRelatedWork W2001578098 @default.
• W4309108432 hasRelatedWork W2006243213 @default.
• W4309108432 hasRelatedWork W2024463098 @default.
• W4309108432 hasRelatedWork W2062554995 @default.
• W4309108432 hasRelatedWork W2100029565 @default.
• W4309108432 hasRelatedWork W2168580276 @default.
• W4309108432 hasRelatedWork W2393063064 @default.
• W4309108432 hasRelatedWork W3021369409 @default.
• W4309108432 hasRelatedWork W4284884935 @default.
• W4309108432 hasVolume "82" @default.
• W4309108432 isParatext "false" @default.
• W4309108432 isRetracted "false" @default.
• W4309108432 workType "article" @default.